COMT Inhibition Among Individuals With Comorbid AUD/ADHD
A legfontosabb adatok
- Ki végzi
- University of Colorado, Denver
- Hol
- Aurora (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 23 fő vett részt
- Kezdés
- 2021. aug. 16.
- Befejezés
- 2026. márc. 9.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Tolcapone
- Placebo
- A regiszteradat frissítve
- 2026. május 4.
Ki vehet részt
- Életkor
- 21 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Age 21-65
- Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current Alcohol Use Disorder (AUD) and current Attention-Deficit/Hyperactivity Disorder (ADHD), as assessed by the Structured Clinical Interview for DSM-5 (SCID-5) or WHO-ASRS
- Currently not engaged in, and does not want treatment for, AUD or ADHD
- Currently not taking any medication for AUD or ADHD
- Able to read and understand questionnaires and informed consent
- Lives within 50 miles of the study site
Ki nem vehet részt
- Any psychoactive substance use (except nicotine) within the last 30 days, as indicated by self-report and urine drug screen (UDS)
- Current use of any psychoactive medication, as evidenced by self-report and UDS
- Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder
- Current DSM-5 psychotic, mood, anxiety, obsessive-compulsive, trauma-related, or eating disorder, as assessed by SCID-5
- History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar)
- Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer
- History of neurological disease or head injury with > 2 minutes of unconsciousness
- Current or past hepatocellular disease, as indicated by verbal report, or elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the upper limit of the normal range at screening
- Current suicidal ideation or homicidal ideation
- Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems, as evidenced by medical history and physical exam
- Females of childbearing potential who are pregnant (by plasma HCG), nursing, or who are not using a reliable form of contraception
- Current charges pending for a violent crime (not including DUI-related offenses)
- Lack of a stable living situation
- Presence of ferrous metal in the body, as evidenced by metal screening and self-report
- Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner
Helyszínek itt: Egyesült Államok
- University of Colorado Anschutz Medical CampusAurora, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, affects response to alcohol, decision-making, brain activation associated with alcohol cue reactivity, response inhibition, and selective attention, or alcohol drinking.
A vizsgálat 2 csoportja
- Tolcapone then PlaceboA vizsgált kezelés
Participants in this arm will receive tolcapone during the first medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8), and placebo during the second medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8).
Kezelés: Tolcapone és Placebo
- Placebo then TolcaponeA vizsgált kezelés
Participants in this arm will receive placebo during the first medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8), and tolcapone during the second medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8).
Kezelés: Tolcapone és Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- COMT Inhibition as a Potential Therapeutic Target Among Individuals With Comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder
- A regiszteradat frissítve
- 2026. május 4.